147 related articles for article (PubMed ID: 28039844)
1. Low-molecular weight heparin versus vitamin K antagonists for the treatment of cancer-associated thrombosis: A cost-effectiveness analysis.
Connell NT; Abel GA; Connors JM
Thromb Res; 2017 Feb; 150():53-58. PubMed ID: 28039844
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrences.
Lanitis T; Leipold R; Hamilton M; Rublee D; Quon P; Browne C; Cohen AT
BMC Health Serv Res; 2017 Jan; 17(1):74. PubMed ID: 28114939
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of Apixaban Versus Other Oral Anticoagulants for the Initial Treatment of Venous Thromboembolism and Prevention of Recurrence.
Lanitis T; Leipold R; Hamilton M; Rublee D; Quon P; Browne C; Cohen AT
Clin Ther; 2016 Mar; 38(3):478-93.e1-16. PubMed ID: 26922297
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness Analysis for Apixaban in the Acute Treatment and Prevention of Venous Thromboembolism in the Netherlands.
de Jong LA; Dvortsin E; Janssen KJ; Postma MJ
Clin Ther; 2017 Feb; 39(2):288-302.e4. PubMed ID: 28139289
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of apixaban compared to low-molecularweight heparins and vitamin k antagonists for treatment and secondary prevention of venous thromboembolism.
Elías I; Oyagüez I; Alvarez-Sala LA; García-Bragado F; Navarro A; González P; De Andrés-Nogales F; Soto J
Farm Hosp; 2016 May; 40(3):187-208. PubMed ID: 27145388
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism.
Lefebvre P; Coleman CI; Bookhart BK; Wang ST; Mody SH; Tran KN; Zhuo DY; Huynh L; Nutescu EA
J Med Econ; 2014 Jan; 17(1):52-64. PubMed ID: 24156243
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of rivaroxaban for treatment and secondary prevention of venous thromboembolism in the Netherlands.
Heisen M; Treur MJ; Heemstra HE; Giesen EBW; Postma MJ
J Med Econ; 2017 Aug; 20(8):813-824. PubMed ID: 28521540
[TBL] [Abstract][Full Text] [Related]
8. LMWH in cancer patients with renal impairment - better than warfarin?
Bauersachs RM
Thromb Res; 2016 Apr; 140 Suppl 1():S160-4. PubMed ID: 27067971
[TBL] [Abstract][Full Text] [Related]
9. Total costs of treating venous thromboembolism: implication of different cost perspectives in a Danish setting.
Nielsen A; Poulsen PB; Dybro L; Kloster B; Lorentzen A; Olsen J; Kümler T
J Med Econ; 2019 Dec; 22(12):1321-1327. PubMed ID: 31516054
[No Abstract] [Full Text] [Related]
10. Economic Analysis Comparing Dalteparin to Vitamin K Antagonists to Prevent Recurrent Venous Thromboembolism in Patients With Cancer Having Renal Impairment.
Dranitsaris G; Shane L; Burgers L; Woodruff S
Clin Appl Thromb Hemost; 2016 Oct; 22(7):617-26. PubMed ID: 27436663
[TBL] [Abstract][Full Text] [Related]
11. A feasibility study to inform the design of a randomised controlled trial to identify the most clinically effective and cost-effective length of Anticoagulation with Low-molecular-weight heparin In the treatment of Cancer-Associated Thrombosis (ALICAT).
Noble SI; Nelson A; Fitzmaurice D; Bekkers MJ; Baillie J; Sivell S; Canham J; Smith JD; Casbard A; Cohen A; Cohen D; Evans J; Fletcher K; Johnson M; Maraveyas A; Prout H; Hood K
Health Technol Assess; 2015 Oct; 19(83):vii-xxiii, 1-93. PubMed ID: 26490434
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of low-molecular-weight heparin for secondary prophylaxis of cancer-related venous thromboembolism.
Aujesky D; Smith KJ; Cornuz J; Roberts MS
Thromb Haemost; 2005 Mar; 93(3):592-9. PubMed ID: 15735815
[TBL] [Abstract][Full Text] [Related]
13. Economic and utilization outcomes associated with choice of treatment for venous thromboembolism in hospitalized patients.
Knight KK; Wong J; Hauch O; Wygant G; Aguilar D; Ofman JJ
Value Health; 2005; 8(3):191-200. PubMed ID: 15877591
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of edoxaban vs low-molecular-weight heparin and warfarin for cancer-associated thrombosis in Brazil.
Lopes DG; Tamayo A; Schipp B; Siepmann T
Thromb Res; 2020 Dec; 196():4-10. PubMed ID: 32810773
[TBL] [Abstract][Full Text] [Related]
15. Anticoagulation in ambulatory cancer patients with no indication for prophylactic or therapeutic anticoagulation: a cost-effectiveness analysis from a U.S. perspective.
Pishko AM; Smith KJ; Ragni MV
Thromb Haemost; 2012 Aug; 108(2):303-10. PubMed ID: 22627904
[TBL] [Abstract][Full Text] [Related]
16. Deep venous thrombosis and pulmonary embolism. Part 2--Prevention of recurrences: warfarin or low-molecular-weight heparin for at least 3 months.
Prescrire Int; 2013 May; 22(138):129-33. PubMed ID: 23819181
[TBL] [Abstract][Full Text] [Related]
17. Long-term use of different doses of low-molecular-weight heparin versus vitamin K antagonists in the treatment of venous thromboembolism.
Romera-Villegas A; Cairols-Castellote MA; Vila-Coll R; Martí-Mestre X; Colomé E; Iguaz I
Ann Vasc Surg; 2010 Jul; 24(5):628-39. PubMed ID: 19932949
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness Analysis of Direct Oral Anticoagulants Versus Vitamin K Antagonists for Venous Thromboembolism in China.
Sun KX; Cui B; Cao SS; Huang QX; Xia RY; Wang WJ; Wang JW; Yu F; Ding Y
Front Pharmacol; 2021; 12():716224. PubMed ID: 34744710
[No Abstract] [Full Text] [Related]
19. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis.
Gould MK; Dembitzer AD; Sanders GD; Garber AM
Ann Intern Med; 1999 May; 130(10):789-99. PubMed ID: 10366368
[TBL] [Abstract][Full Text] [Related]
20. Dalteparin or vitamin K antagonists to prevent recurrent venous thromboembolism in cancer patients: a patient-level economic analysis for France and Austria.
Dranitsaris G; Shane LG; Galanaud JP; Stemer G; Debourdeau P; Woodruff S
Support Care Cancer; 2017 Jul; 25(7):2093-2102. PubMed ID: 28204995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
